XML 52 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8
Collaboration Revenue (Tables)
 9 Months Ended
Sep. 30, 2013
Collaboration Revenue Disclosure [Abstract]  
collaboration revenue with related party
The collaboration revenue the Company earned from Sanofi, as detailed below, consisted primarily of reimbursement for research and development expenses that the Company incurred, the Company's share of losses in connection with Sanofi's commercialization of ZALTRAP®, recognition of a substantive milestone payment in the third quarter of 2012 related to FDA approval of ZALTRAP, and revenue related to non-refundable up-front payments.
In addition, Sanofi collaboration revenue for the nine months ended September 30, 2013 was reduced by two $10.0 million up-front payments to Sanofi in connection with the Company's acquisition from Sanofi of full exclusive rights to two families of novel antibodies, as described below.
 
 
Three months ended
September 30,
Sanofi Collaboration Revenue
 
2013
 
2012
ZALTRAP:
 
 
 
 
Regeneron's share of losses in connection with commercialization of ZALTRAP
 
$
(6,575
)
 
$
(7,390
)
Substantive milestone payment
 


 
50,000

Reimbursement of Regeneron research and development and other expenses
 
2,557

 
2,079

Recognition of deferred revenue related to up-front payments
 
1,384

 
2,889

Total ZALTRAP
 
(2,634
)
 
47,578

Antibody:
 
 
 
 
Reimbursement of Regeneron research and development expenses
 
134,432

 
94,903

Recognition of deferred revenue related to up-front and other payments
 
2,162

 
2,162

Recognition of revenue related to VelociGene® agreement
 
399

 
399

Total Antibody
 
136,993

 
97,464

Total Sanofi collaboration revenue
 
$
134,359

 
$
145,042

 
 
Nine months ended September 30,
Sanofi Collaboration Revenue
 
2013
 
2012
ZALTRAP:
 
 
 
 
Regeneron's share of losses in connection with commercialization of ZALTRAP
 
$
(22,581
)
 
$
(19,525
)
Substantive milestone payment
 


 
50,000

Reimbursement of Regeneron research and development and other expenses
 
7,955

 
9,124

Recognition of deferred revenue related to up-front payments
 
4,152

 
8,260

Total ZALTRAP
 
(10,474
)
 
47,859

Antibody:
 
 
 
 
Reimbursement of Regeneron research and development expenses
 
341,952

 
263,504

Up-front payments to Sanofi for acquisition of rights related to two antibodies
 
(20,000
)
 


Recognition of deferred revenue related to up-front and other payments
 
6,486

 
6,475

Recognition of revenue related to VelociGene agreement
 
1,197

 
1,197

Total Antibody
 
329,635

 
271,176

Total Sanofi collaboration revenue
 
$
319,161

 
$
319,035
Collaboration revenue
The collaboration revenue the Company earned from Bayer HealthCare is detailed below:
 
 
Three months ended
September 30,
Bayer HealthCare Collaboration Revenue
 
2013
 
2012
Regeneron's net profit in connection with commercialization of EYLEA outside the United States
 
$
31,769

 


Sales and substantive development milestone payments
 
45,000

 
$
15,000

Cost-sharing of Regeneron EYLEA development expenses
 
4,844

 
9,724

Reimbursement of other Regeneron EYLEA expenses
 
4,993

 


Recognition of deferred revenue related to up-front and other milestone payments
 
1,977

 
1,977

 
 
$
88,583

 
$
26,701

 
 
Nine months ended
September 30,
Bayer HealthCare Collaboration Revenue
 
2013
 
2012
Regeneron's net profit in connection with commercialization of EYLEA outside the United States
 
$
57,186

 
 
Sales and substantive development milestone payments
 
45,000

 
$
15,000

Cost-sharing of Regeneron EYLEA development expenses
 
14,482

 
27,377

Reimbursement of other Regeneron EYLEA expenses
 
11,995

 
 
Recognition of deferred revenue related to up-front and other milestone payments
 
5,931

 
5,931

 
 
$
134,594

 
$
48,308